Ergoteles LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 180 filers reported holding BRIDGEBIO PHARMA INC in Q4 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.

Quarter-by-quarter ownership
Ergoteles LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q4 2022$167,122
-45.7%
21,932
-29.2%
0.01%
-45.5%
Q3 2022$308,000
-93.8%
30,994
-70.9%
0.01%
-94.0%
Q3 2021$4,996,000
+97.3%
106,600
+199.4%
0.18%
+117.9%
Q4 2020$2,532,000
+955.0%
35,600
+456.2%
0.08%
+162.5%
Q3 2020$240,0006,4000.03%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$373,797,00067.28%
Darwin Global Management, Ltd. 2,090,149$128,753,00025.21%
Affinity Asset Advisors, LLC 577,500$35,574,00012.08%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$1,913,356,0009.64%
Perceptive Advisors 7,756,928$477,827,0006.04%
Opaleye Management Inc. 583,767$35,960,0005.28%
MIZUHO MARKETS AMERICAS LLC 171,923$10,590,0004.93%
VIKING GLOBAL INVESTORS LP 26,620,991$1,639,853,0004.88%
Fernwood Investment Management, LLC 151,085$9,307,0003.42%
HHLR ADVISORS, LTD. 5,362,014$330,300,0003.26%
View complete list of BRIDGEBIO PHARMA INC shareholders